Pharmacodynamics of Oxaliplatin-Derived Platinum Compounds During Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Emerging Aspect Supporting the Rational Design of Treatment Protocols-Reference-Cited by-同舟云学术

Pharmacodynamics of Oxaliplatin-Derived Platinum Compounds During Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Emerging Aspect Supporting the Rational Design of Treatment Protocols

Published:2017-02-03 Issue:6 Volume:24 Page:1650-1657
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Löffler Markus W.,Schuster Heiko,Zeck Anne,Quilitz Nicolas,Weinreich Jürgen,Tolios Alexander,Haen Sebastian P.,Horvath Philipp,Löb Stefan,Rammensee Hans-Georg,Königsrainer Ingmar,Königsrainer Alfred,Beckert Stefan

Funder

RanD biotech S.r.l.

Deutsche Forschungsgemeinschaft

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

http://link.springer.com/content/pdf/10.1245/s10434-017-5790-x.pdf

Reference34 articles.

1. Lambert LA. Looking up: recent advances in understanding and treating peritoneal carcinomatosis. CA Cancer J Clin. 2015;65:283–98.

2. Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30:2449–56.